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ABSTRACT
Aims Evaluation of the efﬁcacy and safety of slow-release oral morphine (SROM) compared with methadone for
detoxiﬁcation from methadone and SROM maintenance treatment. Design Randomized, double-blind, double-
dummy, comparative multi-centre study with parallel groups. Setting Three psychiatric hospitals in Austria special-
izinginin-patientdetoxiﬁcation.Participants Maleandfemaleopioiddependents(age > 18 years)willingtoundergo
detoxiﬁcation from maintenance therapy in order to reach abstinence. Interventions Abstinence was reached
from maintenance treatment by tapered dose reduction of either SROM or methadone over a period of 16 days.
Measurements Efﬁcacy analyses were based on the number of patients per treatment group completing the study, as
well as on the control of signs and symptoms of withdrawal [measured using Short Opioid Withdrawal Scale (SOWS)]
andsuppressionof opiatecraving.Inaddition,self-reportedsomaticandpsychicsymptoms(measuredusingSymptom
Checklist SCL-90-R) were monitored. Findings Of the 208 patients enrolled into the study, 202 were eligible for
analysis (SROM: n = 102, methadone: n = 100). Completion rates were 51% in the SROM group and 49% in the
methadone group [difference between groups: 2%; 95% conﬁdence interval (CI): -12% to 16%]. The rate of discon-
tinuation in the study was high mainly because of patients voluntarily withdrawing from treatment. No statistically
signiﬁcant differences between treatment groups were found in terms of signs and symptoms of opiate withdrawal,
craving for opiates or self-reported symptoms. SROM and methadone were both well tolerated. Conclusions Detoxi-
ﬁcation from maintenance treatment with tapered dose reduction of SROM is non-inferior to methadone.
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INTRODUCTION
Long-term maintenance treatment with opioid agonists
is a medically signiﬁcant approach for harm reduction in
opioid dependence and has an important positive impact
on public health [1]. The beneﬁts of maintenance treat-
ment are well documented, with several reports showing
positiveeffectsonindicatorsincludingmortality,physical
health, risk behaviour and transmission of drug-related
infectious diseases [2–5].
Although maintenance treatment is considered
nowadays to be the gold standard for management of
opioid dependence, detoxiﬁcation is still a common and
frequently demanded therapeutic modality. The primary
emphasis of detoxiﬁcation is not to achieve abstinence
directly;rather,itmaybetheﬁrststeptowardsalternative
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detoxiﬁcation treatment vary considerably, including
desiretoreduceillicitdruguseorgainabrief respitefrom
a life-style complicated by consumption of illicit drugs, or
betheﬁrstoroneof severalattemptstoattainadrug-free
life. Importantly, detoxiﬁcation may offer a period of time
allowing for physical and mental recovery after uncon-
trolled drug use on the way to improving the patient’s
living conditions. Hence, detoxiﬁcation can be a gateway
to multiple treatment options, and can support the
engagement in long-term treatment that is necessary fol-
lowing opioid dependence [8].
Although there are different approaches to pharma-
cological interventions and psychosocial therapy in the
detoxiﬁcationsetting,overallcompletionratesof different
detoxiﬁcation regimens are generally low [6,9,10].
Tapered dose-reduction regimens over a period of 2–3
weeks are common in Austria, and are generally state-
funded. During this period patients undergo supportive
psychotherapyduringgrouptreatmentsessionsandindi-
vidual social counselling. In addition, scheduled occupa-
tional therapy, physiotherapy and sports activities offer
additional support during hospitalization. In Austria,
more than 1000 opioid-dependent patients are referred
per annum to ﬁve specialized in-patient wards—total
capacity approximately 65 beds—linked primarily to
psychiatric hospitals [11]. However, detoxiﬁcation
programmes are facing several challanges: increasing
numbers of patient referrals; increasing length of
waiting lists (approximately 3–4 months); and a reason-
ably high number of patients undergoing maintenance
treatment with slow-release oral morphine (SROM).
The high proportion of patients under maintenance
treatment with SROM in Austria is due to pioneering
treatment programmes offering alternatives to metha-
done and buprenorphine, with the aim of achieving
individualized treatment. The high number of SROM
prescriptions can be related to the favourable side-effect
proﬁle of morphine [12,13]. Several studies have evalu-
ated SROM as a maintenance treatment, and promising
results from some of these suggest that SROM may chal-
lenge the position of methadone as the gold standard of
treatment [14–17]. SROM was found to induce signiﬁ-
cantly less craving for heroin and alcohol, less depression
and fewer physical complaints than methadone in these
studies. Patient perceptions of improved wellbeing with
SROM have led to greater acceptance by patients and a
subsequent increase in its use in clinical practice. Based
on this increasing patient acceptance of SROM as main-
tenancetreatment,itisclinicallyimportanttoinvestigate
a suitable dosage regimen for SROM as an alternative to
methadone for detoxiﬁcation treatment. Morphine is par-
ticularly useful within opioid detoxiﬁcation procedures
whenitisadministeredorallyoncedailyinaslow-release
formulation [18]. The preliminary experience of the
authors of this paper with a limited number of patients
conﬁrmed the validity of this pharmacological concept.
These initial ﬁndings from experienced psychiatrists were
encouraging,butneededtobeconﬁrmedinaprospective,
controlled trial. Here we report the ﬁrst prospective,
controlled clinical study comparing the efﬁcacy, safety
and tolerability of SROM versus methadone in opioid-
dependent in-patients receiving opioid substitution treat-
ment consenting to detoxiﬁcation. The aim of this study
was to evaluate whether detoxiﬁcation with tapered dose
reduction of SROM is non-inferior to methadone as mea-
sured by completion rate of the detoxiﬁcation procedure.
METHODS
Ethical considerations
The study protocol was reviewed and approved by the
ethics committee at each participating centre. The study
was conducted in accordance with the Austrian Medici-
nal Act (BGBl 185/1983). All subjects were provided
with oral and written information describing the nature
and duration of the study. Written informed consent was
obtained from each participant.
Participants
Thisstudywasperformedatthreepsychiatrichospitalsin
Austria specializing in in-patient detoxiﬁcation treat-
ment. All patients underwent long-term opioid substitu-
tion treatment on an out-patient basis prior to admission
to the hospital. Male and female patients over the age of
18 years with a conﬁrmed diagnosis of opioid addiction
according to ICD-10 criteria, who had received mainte-
nance treatment with either SROM (daily doses 320–
960 mg) or methadone (daily doses 40–120 mg) at
constant doses for 1 month, were eligible to enter the
study. In addition, the following inclusion criteria were
applied: alcohol consumption of <100 g/day during the
last 4 weeks; reliable contraceptive methods (hormonal,
non-hormonal)forfemalepatientsof childbearingpoten-
tial. Occasional (but not daily) consumption of cocaine
was acceptable. Patients were excluded from the study if
they had clinically signiﬁcant somatic illness (except
hepatitis), acute psychotic illnesses (i.e. known schizo-
phrenia or major depression with suicidal intent) or
known contraindications to morphine or methadone.
Patients were also excluded if they had received mainte-
nance treatment with other opioids (e.g. buprenorphine,
codeinederivatives)orwereunwillingtofollowinvestiga-
tor instructions. At the investigators’ discretion, patients
who were unsuitable to participate in the study for any
otherreasonwerealsoexcluded,e.g.thoseawaitingcourt
appearances during the following 4-week period.
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This was a multi-centre, randomized, double-blind,
parallel group comparative study. After admission to
hospital, patients continued with their previous mainte-
nancetreatmentfor3consecutivedaysonconstantdoses
(run-in phase: days -2 to 0). During the ﬁrst 2 days
patients were screened under open conditions for poten-
tial participation and were assigned to one of four dose
levels depending on their previous maintenance dose
(level 1: SROM 960–800 mg or methadone 120–
100 mg; level 2: SROM <800–630 mg or methadone
<100–80 mg; level 3: SROM <630–480 mg or metha-
done <80–60 mg; level 4: SROM <480–320 mg or
methadone <60–40 mg). After veriﬁcation of the inclu-
sion and exclusion criteria and receipt of signed consent,
each subject was assigned randomly to receive either
SROM or methadone according to a stratiﬁed randomiza-
tion based on previous drug for maintenance treatment
and dose level. Dose reduction regimens were based on a
dose ratio of SROM : methadone of 8 : 1 whenever pos-
sible at each day (level 1: SROM 780 mg or methadone
98 mg;level2:SROM630 mgormethadone79 mg;level
3: SROM 480 mg or methadone 60 mg; Level 4: SROM
330 mgormethadone42 mg).Thesestartingdoseswere
maintained for 3 consecutive days under double-blind
conditions(dose-adaptationphase:days1–3).Thereafter,
detoxiﬁcation was initiated by tapered dose reductions
overaperiodof 16 daysinordertoreachabstinencefor3
days (detoxiﬁcation phase: days 4–22). Schedules for
tapered dose reductions are presented in Fig. 1.
Study drugs were manufactured by Dr Kolassa and
Merz GmbH (Vienna, Austria). For each patient an indi-
vidual medication box was supplied with 22 bottles
containing six identical capsules to ensure double-blind
conditions (seven capsules for dose level 1 for days 1–3).
Individual daily doses were prepared as capsules ﬁlled
with different amounts of either SROM (morphine sul-
phate slow-release multi-particulate pellets: 200 mg,
120 mg and 30 mg) or methadone (methadone hydro-
chloride mixed with inert excipients for oral administra-
tion as solid form: 15 mg, 8 mg and 4 mg) and lactose
(placebo), respectively. During the dose-adaptation phase
rescue medication was made available to be taken in the
late afternoon (levels 1 and 2: 120 mg SROM or 15 mg
methadone; levels 3 and 4: 60 mg SROM or 8 mg metha-
done). The study drug was administered every morning
under supervision. All comorbid diseases or medical
conditions were treated in accordance with prevailing
medical practice. Mirtazapine, quetiapine, topiramate,
zolpidem, prothipendyl, magnesium preparations, parac-
etamol and naproxen were permitted as concomitant
medications. Monoamine oxidase (MAO)-inhibitors,
clonidine, doxepine, anti-spastic drugs, beta-blockers,
lofexidine and tizanidine were not permitted. Patients
with unbearable signs and symptoms of withdrawal
during the detoxiﬁcation phase were removed prema-
turely from the study.
Objectives
The primary objective of this study was to evaluate
whether detoxiﬁcation with tapered dose reduction of
SROM is non-inferior to methadone with tapered dose
reduction over a period of 16 days followed by 3 days of
abstinence, evaluated by the completion rate of the
detoxiﬁcation phase. Non-inferiority could be stated
according to criteria outlined in the Statistical methods
section. Secondary objectives were to compare the two
treatments with respect to patient-reported outcomes,
such as signs and symptoms of opioid withdrawal,
craving for opioids and other psychoactive compounds,
general wellbeing, illicit drug consumption and safety.
Outcomes
At study entry all patients underwent a physical exami-
nation, including a full evaluation of previous and
co-existing somatic and psychiatric disease and medical
history.Inaddition,AddictionSeverityIndices(ASI)were
rated using the European ASI questionnaire [19]. The
primary efﬁcacy variable was study completion rate, i.e.
the number of patients reaching 3 days at ‘0’ drug level
after tapered dose reduction (i.e. at day 22). Secondary
Figure 1 Dose reduction scheme of slow-release oral morphine (SROM) and methadone (level 1 , level 2 , level 3 ¥, level 4 )
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toms of opioid withdrawal [12-item German version of
theShortOpioidWithdrawalScale(SOWS)][20]assessed
on days 0, 3, 7, 10, 14, 18 and 22 by patient self-rating;
somatic and psychological symptoms [Symptom Check-
list (SCL-90-R)] [21] assessed on days 0, 7, 14 and 22,
from which global symptom scale scores were calculated;
cravingforheroin,alcohol,benzodiazepines,cocaineand
cannabis (rated by patients on a visual analogue scale:
0m m= no craving, 100 mm = most intense craving)
assessed on days 0, 3, 7, 10, 14, 18 and 22. All assess-
ments were performed within 2 hours after intake of the
study drug. In addition, consumption of illicit drugs was
monitored. Blood samples were drawn immediately
before administering the study drug on days 0, 7, 14 and
22 and analysed by tandem mass spectrometry to detect
amphetamines, buprenorphine, cocaine and metabo-
lites, benzodiazepines (ﬂunitrazepam, lorazepam, oxaze-
pam), ketamine,3,4methylenedioxymethamphetamine
(MDMA) (‘ecstasy’), methadone, methamphetamine,
monoacetylmorphine (6-MAM), morphine, phencyclid-
ine (PCP), tetrahydrocannabinol (THC) and tramadol.
Safety was assessed according to serious adverse event
criteria and by recording of spontaneously reported
adverse events, daily monitoring of vital signs (body
weight monitored weekly), repeated physical examina-
tionandclinicallaboratorydata(day0andatstudyend).
Statistical methods
All analyses were performed on an ‘intent-to-treat’
basis. All P-values reported are two-tailed, with P < 0.05
considered statistically signiﬁcant. The primary efﬁcacy
variable was the completion rate in each group. To test
the hypothesis of non-inferiority of the SROM group in
comparison to the methadone group, the 95% conﬁ-
dence interval (CI) of the difference in the completion
rates was calculated. Non-inferiority of the SROM group
could be stated if the lower limit of the CI, for a
maximum acceptable difference in completion rates of
-3%, did not exceed -15%, which was deﬁned as a clini-
cally acceptable non-inferiority limit [22]. A sample size
of 95 evaluable patients per group was estimated to be
sufﬁcient to test the non-inferiority hypothesis with a
power of 80%.
Demographic and background information, as well as
secondary efﬁcacy variables, were summarized and dis-
played using descriptive statistical techniques. Categori-
cal variables are presented in frequency tables, whereas
continuous variables are described using mean, standard
deviation and median. To explore the comparability of
data between study groups, data were analysed depen-
dent on their distribution (Mann–Whitney U-test; c2
test). Intra-group comparisons (day 0 versus day 22)
were performed using the Wilcoxon matched-pairs
signed-ranktest.ThesetestsandtheirassociatedP-values
were regarded as descriptive and not as tests of hypoth-
eses.Astherewasonlyoneprimaryend-point,noadjust-
ment for multiple testing was applicable.
RESULTS
A total of 982 patients who were hospitalized for detoxi-
ﬁcation from maintenance treatment with either SROM
or methadone were screened during the study period. Of
these, 600 (61%) patients did not meet the inclusion cri-
teria and 174 (18%) refused to participate in the study.
Reasons for not meeting the inclusion criteria were:
signiﬁcant comorbidity (n = 168, 17%; maintenance
dose too high or low (n = 107, 11%); high co-
consumption of cocaine and/or alcohol (n = 73, 7%);
slow (>4 weeks) detoxiﬁcation regimen (n = 59, 5%); and
other reasons/no information (n = 193, 20%).
Two hundred and eight (21%) patients were random-
ized into the study (117 patients at the centre in Mauer,
74 in Hall and 27 in Vienna). Six patients withdrew
consent before any administration of study drug (three
patientsfromeachgroup).Twohundredandtwopatients
were eligible for efﬁcacy and safety analysis (SROM:
n = 102; methadone: n = 100). Four patients in the
SROM group received tramadol as concomitant medica-
tion due to withdrawal symptoms, thus violating the
protocol (Fig. 2).
All patients had received previous treatment with
SROM (n = 155, 77%) or methadone (n = 47, 23%) in
accordancewiththeinclusioncriteria.Treatmentgroups
were homogeneous with respect to type (P = 0.450) and
dose levels (P = 0.920) of previous treatment. At study
entry, the two treatment groups were similar in demo-
graphic and disease-related variables, such as medical
history. All patients had a high rate of somatic and psy-
chiatric comorbidities typical for this patient population.
The only signiﬁcant difference between treatment groups
in these baseline parameters was hepatitis C positivity
(P = 0.043) (Table 1). Findings from physical examina-
tion, recording of vital functions [systolic/diastolic blood
pressure, heart rate, electrocardiogram (ECG), body
weight]andlaboratoryparametersshowednodifferences
betweentreatmentgroups.Furthermore,patientsinboth
treatment groups had similar ratings regarding all sub-
domains of the ASI illicit drug use (Table 1).
Completion rate per treatment group was 51% in the
SROM group and 49% in the methadone group. The dif-
ference in completion rates between SROM and metha-
done groups was 2% (95% CI: -12% to 16%). Therefore,
according to the a priori-deﬁned non-inferiority margin
of -15%, SROM is non-inferior to methadone for detoxi-
ﬁcation (Fig. 3).
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treatment groups (SROM 49%, methadone 51%); eight
patients in each group were withdrawn prematurely by
the investigator. Twenty-eight (56%) patients in the
SROM group and 36 (71%) in the methadone group who
withdrew from the study did so voluntarily [reasons for
voluntary discontinuations: left hospital without stating
anyreason(methadone48%,SROM58%),unwillingness
for further detoxiﬁcation (methadone 28%, SROM 28%)
other reasons/no data (methadone 24%, SROM 14%)].
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Figure 2 Schematic representation of patient ﬂow throughout the study (n=208)
Table 1 Baseline characteristics and addiction history of patients.
SROM (n = 102) Methadone (n = 100) P
Baseline characteristics
Gender—n (%)
Male 78 (76.5) 74 (74.0) 0.684
Female 24 (23.5) 26 (26.0)
Age (years)
Mean  SD (median) 27.4  6.2 (26.2) 28.2  7.5 (26.0) 0.697
Body mass index (BMI)
Mean  SD (median) 23.3  4.9 (22.7) 23.0  4.3 (22.2) 0.865
Hepatitis B positive—n (%) 6 (5.9) 4 (4.0) 0.538
Hepatitis C positive—n (%) 29 (28.4) 42 (42.0) 0.043
Hepatitis B+C positive—n (%) 32 (31.3) 26 (26.0) 0.399
HIV + hepatitis B+C positive—n (%) 3 (2.9) 1 (1.0) 0.322
Maintenance regimen prior to study entry
SROM—n (%) 76 (74.5) 79 (79.0) 0.450
Methadone—n (%) 26 (25.5) 21 (21.0)
Addiction history
Age (years) at ﬁrst heroin use 17.9  5.2 (17.0) 18.3  5.0 (17.0) 0.325
Years of heroin use 5.2  4.3 (4.0) 4.9  4.4 (4.0) 0.795
Age (years) at ﬁrst cocaine use 18.4  6.7 (18.0) 18.4  7.6 (18.0) 0.852
Age (years) at ﬁrst multisubstance abuse 16.5  6.5 (16.0) 17.8  5.2 (17.0) 0.128
Years of multi-substance abuse 7.7  6.0 (6.0) 7.9  5.6 (6.0) 0.673
Number of in-patient detoxiﬁcations 1.1  3.9 (0.0) 1.0  2.2 (0.0) 0.581
Duration of drug-free period (months) 9.9  21.9 (2.0) 5.7  10.2 (1.0) 0.312
Data presented as mean  standard deviation (SD) (median). HIV: human immunodeﬁciency virus; SROM: slow-release oral morphine.
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drug switched to for detoxiﬁcation had an impact on fre-
quency of withdrawal (c2 = 0.407).
At study entry signs and symptoms of withdrawal
(SOWS scores) were mild but deteriorated steadily over
time (day 0 versus day 22, P < 0.001) (Table 2). The
only difference between the groups was found on day
18 (P = 0.022). All symptoms showed a homogeneous
patternof changes.Thiswasnotreﬂectedinanychanges
in symptoms of psychological distress based on SCL-90-R
assessments.
Craving for opiates varied considerably but was gener-
ally rated as moderate. No changes became evident
during the detoxiﬁcation phase and there were no signiﬁ-
cantdifferencesbetweengroupsorovertime,respectively
[SROM: day 0, 35.4  35.1 (26.5) mm, day 22,
32.0  35.1 (18.5) mm (P = 0.442); methadone: day 0,
38.7  38.6 (27.0) mm, day 22, 36.8  36.5 (25.0)
mm (P = 0.813)] (Fig. 4a). Craving for alcohol, cocaine
and cannabis was low throughout detoxiﬁcation without
any signiﬁcant differences between groups or over time
(Fig. 4b–d).
A total of 53 patients were identiﬁed via blood tests as
having consumed various psychoactive substances on
days7,14and22.Twenty-sevenof thesepatientswerein
the SROM-group and of these, 18 completed the study
and nine did not. Of the 26 patients identiﬁed in the
methadone group, 17 completed and nine did not
(c2 = 0.922).
Adverse events
The incidence of adverse events was low; 16 (16%)
patients in the SROM group and 13 (13%) patients in the
methadone group experienced at least one adverse event
(c2 test, P = 0.586). Thirty of 45 (67%) of all adverse
events were rated as being unrelated, nine (20%) as pos-
sibly related (SROM: six patients; methadone: three
patients) and one (2%) (methadone group) as probably
related to the study drug. The majority of adverse events
(23of 45)weregastrointestinalsystemdisorders,suchas
nausea (three), vomiting (10), dentalgia (ﬁve), followed
by psychiatric disorders (seven of 45, e.g. dysphoria, agi-
tation, depression, panic attacks). Two patients from the
SROM group had to be transferred to another hospital
wardduetocomorbidmedicalconditions,bothunrelated
to study drug. Two patients had to be discontinued from
study drug; one patient on day 3 due to acute hepatitis B,
the other on day 21 because of acute gastroenteritis.
Overall, detoxiﬁcation from maintenance treatment by
decreasing doses of either SROM or methadone was well
tolerated.
Based on scheduled examinations, no particular
changes over time or differences between treatment
groups were observed during the study for physical
examinationsandlaboratoryparameters.However,heart
rates increased signiﬁcantly over time [SROM: day 0,
79.5  12.3 beats per minute (bpm); day 22,
95.5  15.9 bpm (+20%, P < 0.001, Wilcoxon test);
methadone: day 0, 78.3  9.9 bpm; day 22,
94.5  15.4 bpm (+21%, P < 0.001, Wilcoxon test)].
Othervitalfunctionssuchasdiastolic/systolicbloodpres-
sure and body weight changed over time by less than 5%
with no statistically signiﬁcant differences between the
two treatment groups.
DISCUSSION
This is the ﬁrst prospective, randomized, controlled study
to evaluate the feasibility of SROM for detoxiﬁcation of
opioid-dependent patients from maintenance treatment.
This study was powered to prove the non-inferiority of
SROMtomethadone.Theconceptof thisstudywasbased
on preliminary clinical experiences with tapered dose
reductions of SROM over a period of 2–3 weeks in order
to reach abstinence, in accordance with the widely
accepted method of managing opioid withdrawal with
methadone [23–25]. Double-blind conditions were
deemed necessary to minimize potential bias in patient
selection and subjective assessments of efﬁcacy and
safety. Therefore, it was decided that a parallel-group
study under double-blind conditions would be appropri-
ate. In addition, the proportion of patients from each
treatment group reaching a period of 3 drug-free days
was deﬁned as a suitably robust primary end-point to test
the hypothesis of non-inferiority of SROM to methadone
for detoxiﬁcation. Frequent assessments of signs and
symptoms of opioid withdrawal and craving for opiates
were selected as clinically relevant secondary end-points
together with self-assessments of wellbeing.
Based on the primary end-point of this study, tapered
dose reductions of SROM over a 16-day period are non-
inferior to methadone for keeping patients in treatment
andreachinga3-dayperiodof abstinenceindependentof
the starting doses. The completion rate with SROM was
2% higher than for methadone, which was within the
Figure 3 Kaplan–Meier plot of patient discontinuations during the
study [slow-release oral morphine (SROM) —, methadone--- ]
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has shown methadone to be superior to placebo in this
setting [26], and the response rate to methadone in this
study was consistent with that found in other studies
using similar dose-reduction regimens [27,28]. There-
fore, both methadone and SROM can be viewed as supe-
riortoplacebo[22].Inourstudy,c2testsfoundnoimpact
on completion rates of switching from maintenance
treatment with SROM or methadone to detoxiﬁcation
with either SROM or methadone, or of co-consumption.
No differences were found between methadone and
SROM with regard to signs and symptoms of opioid with-
drawal (SOWS scores) and craving for opiates, respec-
tively(secondaryend-point).Furthermore,nodifferences
between treatment groups were found with regard to
wellbeing (SCL-90-R). Co-consumption of illicit sub-
stances was low and similar in both treatment groups.
Although withdrawal symptoms increased slightly
during tapering periods, withdrawal severity for both
drugs were classed as ‘mild’ during these periods. There
was no signiﬁcant increase in subject ratings of craving
throughout the study period. Tolerability of both study
drugs was good. The number of patients who reported
adverse events spontaneously as well as the total number
of adverse events was low in both treatment groups. A
trend for increasing heart rate was observed equally in
both groups and can be attributed to activation of the
noradrenergic pathway [29].
Although non-inferiority of SROM to methadone in a
double-blind randomized study design could be demon-
strated, two conspicuous features of the study warrant
further discussion. First, although 208 patients were
enrolled in the study, only 10% of all patients who were
hospitalized for detoxiﬁcation at the trial centres during
the 2.5-year study period consented to participation in
the study. To explain the low willingness of patients to
participate in the trial, it is important to consider the
circumstances of such patients at admission. Patients
Table 2 Signs and symptoms related to opioid withdrawal and psychological distress.
SROM
Mean  SD (median)
Methadone
Mean  SD (mMedian)
Day 0 (n = 102) Day 22 (n = 52) P Day 0 (n = 99) Day 22 (n = 50) P




0.70  0.56 (0.6) 0.74  0.56 (0.58) 0.326 0.77  0.58 (0.61) 0.67  0.51 (0.52) 0.511
SCL: Symptom Checklist; SROM: slow-release oral morphine; SOWS: Short Opioid Withdrawal Scale; SD: standard deviation.
Figure 4 Craving for opiates,alcohol,cocaine and cannabis [self-assessment via visual analogue scale (VAS) 0=no craving,100=most intense
craving] [slow-release oral morphine (SROM) , methadone ]
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aspecialgroupof opioid-dependentsubjects,astheyhave
various motives to undergo dose reduction in order to
reach abstinence.They are also suffering commonly from
clinically signiﬁcant somatic and psychiatric comorbidi-
ties resulting in high individual stress levels and fear of
detoxiﬁcation [30]. The impact of double-blind study
conditions also warrants consideration; patients were
veryanxiousaboutthefactthatneitherthephysiciannor
they themselves knew which drug was being used for
detoxiﬁcation.
Secondly, the completion rate and discontinuation
rates observed in the present study were both approxi-
mately 50%, consistent with previous research [26,27],
with discontinuations being due primarily to individual
patient choice. Notably, identical discontinuation rates
were recorded at all trial centres for patients treated
under normal conditions not being enrolled into the
study. However, these rates of premature withdrawal
agree with ﬁndings in other studies and are not limited to
detoxiﬁcationprogrammesbutarealsoageneralproblem
in treating substance abuse [10,31].
However, premature termination of opioid detoxiﬁca-
tion is not due necessarily to a failure of treatment. As
discussed earlier, the aim of detoxiﬁcation treatment is
not to enforce abstinence at any cost. Therefore, it is not
unusual that some patients, not being able to sustain
abstinence, revert immediately to maintenance treat-
ment. However, this limited exposure to detoxiﬁcation
can serve as a basis for initiating mental, somatic and
social improvements in an illicit drug addict’s life, inde-
pendent of abstinence or maintenance. The increasing
number of clinical studies in both maintenance and
detoxiﬁcation demontrates the clinical need for individu-
alized treatment programmes based on different medici-
nal products and supportive psychosocial counselling
[32].
Inconclusion,thisprospective,double-blind,random-
ized study with parallel group design proved that opiate-
dependent patients can be detoxiﬁed from maintenance
therapy by tapered dose reductions of SROM or metha-
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